Elevated plasma Sirtuin2 level predicts heart failure after acute myocardial infarction

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Molecular Cardiology

Background:

• The role of plasma Sirtuin2 (SIRT2) in acute myocardial infarction (AMI) remains uncharacterized.
• Investigating novel biomarkers is crucial for improving patient outcomes after AMI.

Purpose of the Study:

• To assess the role of plasma SIRT2 levels in patients with AMI.
• To determine the association between plasma SIRT2 levels and the occurrence of major adverse cardiovascular events (MACE) and heart failure following AMI.

Main Methods:

• Prospective observational study including 129 AMI patients.
• Plasma SIRT2 levels were measured and patients were categorized into high-level and low-level groups based on the 75th percentile.
• Cox proportional hazards regression models were employed to analyze the association with MACE and heart failure.

Main Results:

• Patients with high plasma SIRT2 levels (≥109.0 pg/mL) exhibited a higher prevalence of Killip class ≥3, reduced left ventricular ejection fraction (LVEF), and increased use of mechanical ventilation.
• High SIRT2 levels were significantly associated with elevated plasma brain natriuretic peptide (BNP) levels.
• Multivariate analysis revealed that high plasma SIRT2 levels significantly increased the risk of MACE (HR 11.20) and heart failure (HR 27.10) after AMI.

Conclusions:

• Plasma SIRT2 level is identified as a potential predictive biomarker for heart failure and MACE in AMI patients.
• This finding highlights the clinical utility of assessing plasma SIRT2 for risk stratification in acute myocardial infarction.